Metformin Is Associated with Reduced Tissue Factor Procoagulant Activity in Patients with Poorly Controlled Diabetes

[1]  A. Dörner,et al.  Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes , 2020, Cardiovascular Diabetology.

[2]  S. Felix,et al.  Protease-activated receptor 2 deficiency mediates cardiac fibrosis and diastolic dysfunction. , 2019, European heart journal.

[3]  Zhiguang Zhou,et al.  Metformin shows anti‐inflammatory effects in murine macrophages through Dicer/microribonucleic acid‐34a‐5p and microribonucleic acid‐125b‐5p , 2019, Journal of diabetes investigation.

[4]  S. Solomon,et al.  Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease , 2019, Diabetes, obesity & metabolism.

[5]  S. Balci,et al.  Profiles of Circulating MiRNAs Following Metformin Treatment in Patients with Type 2 Diabetes , 2018, Journal of medical biochemistry.

[6]  A. Dörner,et al.  MicroRNA-19a contributes to the epigenetic regulation of tissue factor in diabetes , 2018, Cardiovascular Diabetology.

[7]  C. N. Ferreira,et al.  Metformin reduces total microparticles and microparticles-expressing tissue factor in women with polycystic ovary syndrome , 2017, Archives of Gynecology and Obstetrics.

[8]  Chen-Song Zhang,et al.  Metformin Activates AMPK through the Lysosomal Pathway. , 2016, Cell metabolism.

[9]  U. Landmesser,et al.  Micro–RNA-126 Reduces the Blood Thrombogenicity in Diabetes Mellitus via Targeting of Tissue Factor , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[10]  U. Landmesser,et al.  Tissue factor as a link between inflammation and coagulation. , 2016, Trends in cardiovascular medicine.

[11]  R. de Cabo,et al.  Metformin‐mediated increase in DICER1 regulates microRNA expression and cellular senescence , 2016, Aging cell.

[12]  M. Witkowski,et al.  The Role of Protease-Activated Receptors for the Development of Myocarditis: Possible Therapeutic Implications. , 2016, Current pharmaceutical design.

[13]  T. Ciaraldi,et al.  Tissue Factor Expression in Obese Type 2 Diabetic Subjects and Its Regulation by Antidiabetic Agents , 2015, Journal of obesity.

[14]  E. Rossmanith,et al.  Monocytes, Peripheral Blood Mononuclear Cells, and THP-1 Cells Exhibit Different Cytokine Expression Patterns following Stimulation with Lipopolysaccharide , 2013, Mediators of inflammation.

[15]  B. Okopień,et al.  The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose. , 2013, Metabolism: clinical and experimental.

[16]  B. Osterud,et al.  Cardiovascular complications of diabetes mellitus: The Tissue Factor perspective. , 2010, Thrombosis research.

[17]  James L. Young,et al.  Metformin Inhibits Proinflammatory Responses and Nuclear Factor-&kgr;B in Human Vascular Wall Cells , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[18]  H. Schultheiss,et al.  Procoagulant Soluble Tissue Factor Is Released From Endothelial Cells in Response to Inflammatory Cytokines , 2005, Circulation research.

[19]  P. Libby,et al.  Hypochlorous Acid, a Macrophage Product, Induces Endothelial Apoptosis and Tissue Factor Expression: Involvement of Myeloperoxidase-Mediated Oxidant in Plaque Erosion and Thrombogenesis , 2004, Arteriosclerosis, thrombosis, and vascular biology.